Breaking News Instant updates and real-time market news.

NKTR

Nektar

$39.99

0.98 (2.51%)

09:03
11/06/18
11/06
09:03
11/06/18
09:03

Nektar abstract references old 50% ORR, says Piper Jaffray

The regular Society for Immunotherapy of Cancer abstract that provides an update of the first line melanoma patient cohort in the ongoing PIVOT-02 trial testing the combination of Nektar Therapeutics's NKTR-214 plus Opdivo was posted, Piper Jaffray analyst Tyler Van Buren tells investors in a research note. He points out that 41 patients were enrolled with 38 evaluable for efficacy and the investigator-assessed objective response rate as of July 12 was 50%. Van Buren says that while is this is what we already knew, it confirms his prior assumption of the 50% response rate floor heading into the Friday afternoon updated data presentation. On Friday, the analyst expects to receive an updated response rate and more details on the quality of response. Finally, no responder has relapsed in this cohort and median duration of response has not been reached, which is promising as we begin to think about the probability of success for the Phase III trial, says the analyst. Shares of Nektar are down 7%, or $2.75, to $37.25 in pre-market trading.

  • 07

    Nov

  • 07

    Nov

  • 10

    Nov

  • 12

    Nov

  • 27

    Nov

NKTR Nektar
$39.99

0.98 (2.51%)

08/08/18
PIPR
08/08/18
NO CHANGE
Target $125
PIPR
Overweight
Nektar offered more 'granularity' on PIVOT data timing, says Piper Jaffray
Piper Jaffray analyst Tyler Van Buren kept his Overweight rating and $125 price target on Nektar after its Q2 earnings beat, saying the management has also offered more detail on the company's data release plans. The analyst sees the 1L melanoma cohort readout coming before the end of 2018, followed by RCC and bladder cancer data likely in the first half of 2019 and other tumor types later next year. Van Buren adds that these disclosures should hopefully add to the company's understanding about the efficacy of 214+nivo combination therapy.
08/09/18
MZHO
08/09/18
NO CHANGE
Target $103
MZHO
Buy
Nektar to report additional data in coming months, says Mizuho
Mizuho analyst Difei Yang reiterates a Buy rating on Nektar Therapeutics with a $103 price target following last night's Q2 results. Data readouts of NKTR-214 remain the main catalyst for the shares, Yang tells investors in a research note. She points out that management expects to present data at a number of conferences in the coming months, including melanoma data at the Society for Immunotherapy of Cancer on November 7-11. While details on additional data in other indications "were sparse," data should be announced over the coming six-to-eight months, Yang contends.
10/22/18
HCWC
10/22/18
NO CHANGE
Target $54
HCWC
Neutral
Roche data should concern Nektar bulls, says H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay believes Roche's (RHHBY) preliminary data of RO6875281, a fibroblast activation protein targeted interleukin-2 variant, should concern the bulls of Nektar Therapeutics (NKTR). The 11% and 20% overall response rate for single agent RO6875281 in squamous cell head and neck cancer and melanoma is compelling, Chattopadhyay tells investors in a research note. Nektar's NKTR-214 had no monotherapy activity, and the early promise in combination with Opdivo "has faded potentially due to its limited PK profile," the analyst adds. In addition, Chattopadhyay believes the monotherapy activity with pegilodecakin, a pegylated IL-10 being developed by Eli Lily (LLY), further complicates the competitive landscape for NKTR-214. He believes the second generation of "not alpha" IL-2, which is poised to enter the clinic during 2019, could further "upend" NKTR-214 and might compel Nektar's partner Bristol-Myers Squibb (BMY) to "re-evaluate the aggressive development strategy that was outlined earlier this year." The analyst keeps a Neutral rating on Nektar with a $54 price target.
11/05/18
HCWC
11/05/18
NO CHANGE
Target $47
HCWC
Neutral
Nektar price target lowered to $47 from $54 at H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay lowered his price target for Nektar Therapeuticsless than (NKTR) to $47 and keeps a Neutral rating on the shares. While the Phase 3 trial of Opdivo plus NKTR-214 is welcome news, the company faces a crowded frontline renal cell carcinoma treatment landscape and stiff commercial hurdles, Chattopadhyay tells investors in a research note. He believes that unless the NKTR-214 plus Opdivo combination is meaningfully superior to the Opdivo and Yervoy combination, Bristol-Myers (BMY) "may not be willing to muscle the commercial launch, given the cannibalization of its existing franchise."

TODAY'S FREE FLY STORIES

MMTOF

Mitsubishi Motors

$0.00

(0.00%)

06:23
11/16/18
11/16
06:23
11/16/18
06:23
Upgrade
Mitsubishi Motors rating change  »

Mitsubishi Motors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$143.86

-0.39 (-0.27%)

, PUBGY

Publicis

$0.00

(0.00%)

06:22
11/16/18
11/16
06:22
11/16/18
06:22
Periodicals
Facebook lack of morals drawing ire from advertisers, New York Times reports »

Facebook (FB) is coming…

FB

Facebook

$143.86

-0.39 (-0.27%)

PUBGY

Publicis

$0.00

(0.00%)

WPP

WPP

$55.45

-0.65 (-1.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

EVKIF

Evonik

$0.00

(0.00%)

06:20
11/16/18
11/16
06:20
11/16/18
06:20
Downgrade
Evonik rating change  »

Evonik downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLKAY

Volkswagen

$0.00

(0.00%)

06:16
11/16/18
11/16
06:16
11/16/18
06:16
Periodicals
Volkswagen CEO to assume responsibility for China business, Reuters reports »

Volkswagen CEO Herbert…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVDA

Nvidia

$202.65

5.43 (2.75%)

06:13
11/16/18
11/16
06:13
11/16/18
06:13
Recommendations
Nvidia analyst commentary  »

Nvidia price target cut…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 26

    Nov

  • 10

    Dec

YEXT

Yext

$17.44

0.35 (2.05%)

06:08
11/16/18
11/16
06:08
11/16/18
06:08
Initiation
Yext initiated  »

Yext initiated with a Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

PLUS

ePlus

06:07
11/16/18
11/16
06:07
11/16/18
06:07
Initiation
ePlus initiated  »

ePlus initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENR

Energizer

$51.44

-4.51 (-8.06%)

06:07
11/16/18
11/16
06:07
11/16/18
06:07
Downgrade
Energizer rating change  »

Energizer downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$143.86

-0.39 (-0.27%)

06:06
11/16/18
11/16
06:06
11/16/18
06:06
Periodicals
Zuckerberg says he's still the best person to run Facebook, BI reports »

CEO Mark Zuckerberg…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

TKPYY

Takeda Pharmaceutical

$0.00

(0.00%)

, SHPG

Shire

$178.98

-1.15 (-0.64%)

06:06
11/16/18
11/16
06:06
11/16/18
06:06
Periodicals
Takeda dissident shareholders make final push to stop Shire deal, FT reports »

A dissident group of…

TKPYY

Takeda Pharmaceutical

$0.00

(0.00%)

SHPG

Shire

$178.98

-1.15 (-0.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 21

    Dec

SBRA

Sabra Health Care

$19.12

-0.52 (-2.65%)

06:06
11/16/18
11/16
06:06
11/16/18
06:06
Downgrade
Sabra Health Care rating change  »

Sabra Health Care…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OHI

Omega Healthcare

$34.34

-0.13 (-0.38%)

06:05
11/16/18
11/16
06:05
11/16/18
06:05
Upgrade
Omega Healthcare rating change  »

Omega Healthcare upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DSW

DSW

$25.39

-0.4 (-1.55%)

06:05
11/16/18
11/16
06:05
11/16/18
06:05
Upgrade
DSW rating change  »

DSW upgraded to Neutral…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BPMX

BioPharmX

$0.18

-0.0032 (-1.77%)

06:05
11/16/18
11/16
06:05
11/16/18
06:05
Hot Stocks
BioPharmX announces NYSE acceptance of plan to regain compliance »

BioPharmX announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVDA

Nvidia

$202.65

5.43 (2.75%)

06:05
11/16/18
11/16
06:05
11/16/18
06:05
Downgrade
Nvidia rating change  »

Nvidia downgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 26

    Nov

  • 10

    Dec

PBA

Pembina Pipeline

06:04
11/16/18
11/16
06:04
11/16/18
06:04
Upgrade
Pembina Pipeline rating change  »

Pembina Pipeline upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EOG

EOG Resources

06:04
11/16/18
11/16
06:04
11/16/18
06:04
Upgrade
EOG Resources rating change  »

EOG Resources upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AFI

Armstrong Flooring

$16.66

1.85 (12.49%)

06:03
11/16/18
11/16
06:03
11/16/18
06:03
Upgrade
Armstrong Flooring rating change  »

Armstrong Flooring…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LGF.A

Lionsgate

$20.52

0.595 (2.99%)

05:59
11/16/18
11/16
05:59
11/16/18
05:59
Upgrade
Lionsgate rating change  »

Lionsgate upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LUV

Southwest

$53.23

0.75 (1.43%)

, BA

Boeing

$341.57

-3.06 (-0.89%)

05:59
11/16/18
11/16
05:59
11/16/18
05:59
Periodicals
Southwest replaced 2 flight-control sensors before Lion Air crash, WSJ reports »

During the three weeks…

LUV

Southwest

$53.23

0.75 (1.43%)

BA

Boeing

$341.57

-3.06 (-0.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLKAY

Volkswagen

$0.00

(0.00%)

05:56
11/16/18
11/16
05:56
11/16/18
05:56
Periodicals
Volkswagen board to vote on multi-billion euro investment plan, Reuters reports »

Volkswagen's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVDA

Nvidia

$202.65

5.43 (2.75%)

05:51
11/16/18
11/16
05:51
11/16/18
05:51
Recommendations
Nvidia analyst commentary  »

Nvidia 'kitchen…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 26

    Nov

  • 10

    Dec

EQH

AXA Equitable

$20.40

-0.49 (-2.35%)

05:51
11/16/18
11/16
05:51
11/16/18
05:51
Syndicate
AXA Equitable 60M share Secondary priced at $20.25 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 16

    Nov

RWLK

ReWalk Robotics

$0.44

-0.1116 (-20.24%)

05:50
11/16/18
11/16
05:50
11/16/18
05:50
Syndicate
ReWalk Robotics raises $11.6M in a public offering »

ReWalk Robotics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNE

Sony

$51.61

0.46 (0.90%)

05:49
11/16/18
11/16
05:49
11/16/18
05:49
Hot Stocks
Sony says has sold 86.1M PS4 units since debut 5 years ago »

Sony says in a blog post…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.